Answers are grounded in this paper and cite their sources.
Amyloid cross-seeding has often been viewed as a “like-seeds-like” extension of homologous nucleation, in which structurally similar amyloid proteins reciprocally accelerate assembly through a shared cross-β architecture. Increasing evidence instead reveals frequent asymmetry: A→B and B→A can differ in rate, mechanism, structural outcome, and biological consequence, and may change with seed state, fibril polymorph, or microenvironment. Here, we propose that productive cross-seeding is governed by directionally selective compatibility rather than generic β-sheet similarity. We examine six mechanistic origins of asymmetry: conformational selection and population shift, fibril-end templating, dock-and-lock kinetic gating, lateral-face recognition, surface-catalyzed secondary nucleation, and coaggregation coupled to strain selection. We integrate kinetic, structural, cellular, animal, and human evidence, emphasizing that bulk aggregation measurements alone cannot distinguish templated elongation from secondary nucleation, adsorption, sequestration, coaggregation, or strain conversion. We further discuss how heterotypic interfaces reshape fibril polymorphism and disease relevance, and assess emerging molecular-simulation and machine-learning approaches for predicting directional cross-seeding. This mechanism-centered framework provides a basis for understanding mixed amyloid pathologies and for developing strategies to block, redirect, or exploit heterotypic propagation in disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: